RT Journal Article
SR Electronic
T1 Antihypertensive medication uses and serum ACE2 levels
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.21.20108738
DO 10.1101/2020.05.21.20108738
A1 Emilsson, Valur
A1 Gudmundsson, Elias F.
A1 Aspelund, Thor
A1 Jonsson, Brynjolfur G.
A1 Gudjonsson, Alexander
A1 Launer, Lenore J.
A1 Jennings, Lori L.
A1 Gudmundsdottir, Valborg
A1 Gudnason, Vilmundur
YR 2020
UL http://medrxiv.org/content/early/2020/05/25/2020.05.21.20108738.abstract
AB Importance Recent reports have shown that hypertension is the most common comorbidity associated with mortality in the current coronavirus disease 2019 (COVID-19). This has been related to the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) as animal studies indicate that these medications increase levels of ACE2, the cellular entry point for the coronavirus SARS-CoV-2. This has prompted clinicians to recommend discontinuing ACEIs and ARBs.Objective To examine the effect of ACEIs or ARBs treatment on serum levels of ACE2 and other key enzymes in the renin-angiotensin system (RAS).Design, Setting, and Participants A single center population-based study of 5457 Icelanders from the Age, Gene/Environment Susceptibility Reykjavik Study (AGES-RS) of the elderly (mean age 75±6 years) stratified by ACEIs (N = 699) or ARBs (N = 753) treatment.Main Outcomes and Measures The AGES-RS study population was stratified by ACEIs and ARBs medication use and compared for age, body mass index (BMI) (kg/m2), hypertension and type 2 diabetes (T2D) as well as serum levels of renin, ACE and ACE2.Results While renin and ACE levels were significantly raised in serum of individuals on ACEIs or ARBs treatments, the ACE2 levels remained unaffected.Conclusions and Relevance Treatment with ACEIs or ARBs does not raise ACE2 levels in serum. Therefore, the present study does not support the proposed discontinuation of these medications among patients affected with COVID-19.Question Does treatment with the antihypertensive medications angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) result in elevated levels of the cellular receptor for the coronavirus SARS-CoV-2, ACE2?Findings In a single center population-based cohort (AGES-RS), 699 and 753 individuals were either on ACEIs or ARBs treatment, respectively. The serum levels of the key enzymes in the renin-angiotensin system (RAS), renin, ACE and ACE2 were measured in 5457 subjects of the AGES-RS and their serum levels in individuals on ACEIs or ARBs treatment compared to those not using these medications. While renin and ACE were significantly raised in serum of ACEIs and ARBs users, the levels of ACE2 remained unaffected.Meaning These results do not support the proposed routine discontinuation of ACEIs or ARBs among patients affected with COVID-19.Competing Interest StatementL.L.J. is an employee of and own stocks in Novartis. All other authors declare they have no competing interests.Funding StatementSupported by Novartis Institute for Biomedical Research (NIBR), Icelandic Heart Association, and in part by the intramural research program at the National Institute of Aging (N01-AG-12100 and HHSN271201200022C).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The AGES-RS was approved by the NBC in Iceland (approval number VSN-00-063), and by the National Institute on Aging Intramural Institutional Review Board (U.S.) and the Data Protection Authority in Iceland.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe custom-design Novartis SOMAscan is available through a collaboration agreement with the Novartis Institutes for BioMedical Research (lori.jennings{at}novartis.com). Data from the AGES Reykjavik study are available through collaboration (AGES_data_request@hjarta.is) under a data usage agreement with the IHA.